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Abstract
To estimate treatment effects, trials are initiated by randomising patients to the interventions under study and finish
by comparing patient evolution. In order to improve the trial report, the CONSORT statement provides authors and
peer reviewers with a guide of the essential items that would allow research replication. Additionally, WebCONSORT
aims to facilitate author reporting by providing the items from the different CONSORT extensions that are relevant
to the trial being reported. WebCONSORT has been estimated to improve the proportion of reported items by 0.04
(95% CI, –0.02 to 0.10), interpreted as “no important difference”, in accordance with the scheduled desired scenario
of a 0.15 effect size improvement. However, in a non-scheduled analysis, it was found that, despite clear
instructions, around a third of manuscripts selected for trials by the editorial staff were not actually randomised
trials. We argue that surprises benefit science, and that further research should be conducted in order to improve
the performance of editorial staff.
Please see related research: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0736-x
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Background
Research should welcome and capitalise on surprises. A
classic example of this occurred when Barry Marshall and
Robin Warren found Helicobacter pylori in a person with
chronic gastritis and gastric ulcers, conditions that were
previously attributed to stress or spicy food [1]. When ser-
endipity helped Alexander Fleming discover penicillin, his
achievement was not in staining a lab plate, but in repro-
ducing the results and advancing the possibilities.
There is a continuous research path from the discov-
ery to the implementation of new interventions. At the
beginning, researchers such as Fleming have ‘an idea’. At
the end, they measure the intervention effect. In other
words, they ask themselves: What would the evolution
be for some patients if, instead of the standard interven-
tion, we provide them the updated one. Since re-
searchers are unable to observe both evolutions in the
same patient, a fairly simple (at least, conceptually)
process is chosen: randomly allocate both treatments to
patients and compare their evolution. This, and nothing
else, is a randomised clinical trial.
Unfortunately, things can go wrong – protocol devia-
tions, unmasked evaluation and sample attrition have
been proven to bias the results [2], and poor methodo-
logical background [3] and conflict of interests [4] may
further misguide authors. Therefore, in order to facilitate
reproducibility, the CONSORT statement [5] has been
developed to guide them in the reporting of essential
items. However, as trials with different objectives, meth-
odologies or types of interventions may need different
essential items, new extensions have been added and
gathered into the EQUATOR website [6]. To facilitate
manuscript preparation, WebCONSORT provides all the
items that apply to the reported trial. In order to esti-
mate the effect of WebCONSORT on manuscript com-
pleteness, Hopewell et al. [7] conducted a randomised
trial in which experimental units were themselves manu-
scripts of randomised clinical trials, and reported that
WebCONSORT improves the proportion of reported
items by 0.04, although random allocation makes this re-
sult compatible (95% CI) with any true value between a
decrease of 0.02 and an improvement of 0.10. The
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authors interpret those values as “no important differ-
ence” [7], in accordance with the scheduled scenario of a
0.15 effect size improvement.
Unexpected findings – editors under the magnifying glass
Looking at additional results, Hopewell et al. [7] showed
no surprise when they found “that in a quarter (23%) of
manuscripts, authors either selected an inappropriate
CONSORT extension or failed to select the right exten-
sion applicable to their trial”. As this agreed with their
prior thoughts, it reinforced their aim to enhance au-
thors’ reporting of randomised trials. However, if there is
no surprise, one may feel that this is a boring result.
Nevertheless, Hopewell et al. [7] “did not anticipate
that journals would enroll manuscripts that were not in
fact reports of randomised trials”. In the Discussion, they
state that: “More than one third (39%) of registered man-
uscripts were excluded from the analysis as they were not
reports of randomised trials. This was despite clear in-
structions provided to journal editorial staff, and in-
cluded in the revision letter to authors, that only
manuscripts reporting the results of randomised trials
were eligible for inclusion. Clearly, the editorial staff at
some journals were unable to correctly identify a rando-
mised trial based on what was reported in the submitted
manuscript”. Further, in their Results section, they de-
scribe the recruitment process: “Between 25 March 2013
and 22 September 2015, 357 manuscripts were registered
on the WebCONSORT study site from 46 general medical
and specialty journals with an impact factor ranging
from 11.34 to 0.65 as of 2014. […] The percentage of eli-
gible manuscripts varied considerably across journals
(median 73%; IQR 27% to 100%).” Thus, randomised tri-
als constitute the methodological gold standard for
assessing treatment effects, but the editorial staff of
medical journals were unable to correctly classify their
own manuscripts as randomised trials. Aha!
In their Discussion, Hopewell et al. [7] state: “Better
education is needed […] for both authors and journal
editorial staff”. This is of no surprise with regards to the
authors; however, in terms of the editorial staff, it ini-
tially seems surprising, yet further consideration reveals
that it may not be so. In order to assess what goes wrong
along the research pipeline, the clinical scientific com-
munity, led by JAMA and BMJ, organises the quadren-
nial Congress on Peer Review in Biomedical Publication,
which is devoted to improving the quality of biomedical
literature [8, 9]. In its inception, the congress initially
concentrated mainly on the peer review process – hence
its name. However, the meeting now includes “featured
research describing poor practices on the parts of au-
thors, reviewers, editors, and journals” [8]. Thus, as edi-
tors and journals are already under the magnifying glass
of investigation, this is of no surprise at all.
Unfortunately, this unanticipated, poor selection made
it impossible to perform the designed intervention on
misclassified manuscripts. Therefore, the WebCON-
SORT authors had to leave out a substantial proportion
of papers, thereby losing the scheduled study power and
thus making interpretation difficult. Nevertheless, the
non-significance of their results should at least be inter-
preted carefully [10].
Surprising unexpected results: what can we learn?
When anyone agrees to participate in clinical research –
whether they be patients, recruiters, interventionists or
raters – they are generously volunteering their time, ef-
forts and data. At every stage of the pipeline, transpar-
ency implies that the scientific community has to be
able to assess what went wrong. Inevitably, researchers
must be unpleasant to these volunteers by asking im-
portant questions, including, Have patients followed the
recommendations? Have recruiters adequately explained
to them how important it is to adhere to the agreed
protocol? Have interventionists applied it carefully? Have
monitors made any effort to complete patient follow-up?
Indeed, clinical science may never have progressed with-
out the noble-mindedness of volunteers.
Along similar lines, while keeping in mind the gener-
osity of everyone involved in peer review research, we
should ponder the questions that the unexpected results
of WebCONSORT have provided: Is there any charac-
teristic among editors or journals that predicts the pro-
portion of correctly classified manuscripts? For example,
is impact factor involved? What is the manuscript
process flow? What are the responsibilities shared by dif-
ferent staff members? What was their selection process?
Are they professional or academic editors? What scientific
and methodological background do they have? Are differ-
ent scientific communities represented in their editorial
staff? The answers will, ideally, lead to more ambitious re-
search questions about the assumed causal factors: Would
the modification of any of them result in the desired im-
provement. Obviously, this process would imply further
generosity from researchers, editors and journals.
Conclusions
The WebCONSORT randomised trial was designed to
test an intervention for improving the transparent
reporting of methods and results by authors. The main
analysis of this objective was performed by following the
most exigent experimental conditions, with the excep-
tion of the already mentioned unexpected loss of power.
However, they also observed that the journal gatekeepers
classified too many manuscripts as randomised trials
when they were not, in fact, so. Shocking? Perhaps.
Nevertheless, this post-hoc data is certainly informative
Cobo and González BMC Medicine  (2016) 14:204 Page 2 of 3
and deserves further study by either the authors of the
WebCONSORT study or the very same editors.
Christopher Columbus was looking for a new path to
Asia. However, to the world’s surprise, he came upon
America. Then, to complete the path from discovery to
innovation, Columbus travelled several other times.
Now, the scientific community must unravel how to im-
prove editors’ performance.
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